Lacosamide is Associated with a Higher Treatment Persistence at 12 Months than Brivaracetam and Perampanel Despite Similar Efficacy

Treatment discontinuation in epilepsy emerges as a dynamic process shaped by both tolerability and clinical response. Early persistence was higher for LCM, whereas long-term retention was improved for BRV and PER. These results support a personalized approach to ASM selection that integrates early tolerability with sustained effectiveness.

Authors

Institutions

Publication Details

Journal
Neurology and Therapy
Published
2025-11-20
DOI
https://doi.org/10.1007/s40120-025-00860-5
Citations
1
Primary Topic
Epilepsy research and treatment
Type
article
Field-Weighted Citation Impact
1.47

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lacosamide is Associated with a Higher Treatment Persistence at 12 Months than Brivaracetam and Perampanel Despite Similar Efficacy

Angela La Neve, Francesca Anzellotti, Payam Tabaee Damavandi, Roberta Roberti et al.
1 citations
Neurology and Therapy
Epilepsy research and treatment
1.47
article

Lacosamide is Associated with a Higher Treatment Persistence at 12 Months than Brivaracetam and Perampanel Despite Similar Efficacy

Angela La Neve, Francesca Anzellotti, Payam Tabaee Damavandi, Roberta Roberti, Angelo Pascarella, Valeria Badioni, Gionata Strigaro, Sara Gasparini, Francesco Fortunato, Vincenzo Belcastro, Andrea Maialetti, Stefano Luca Sensi, Giovanni Falcicchio, Alfonso Giordano, Jacopo Cosimo DiFrancesco, Alberto Danieli, Annacarmen Nilo, Simona Lattanzi, Roberta Di Giacomo, Maria Grazia Pascarella, Giacomo Evangelista, Lorenzo Verriello, Laura Canafoglia, Mariana Fernandes, Simone Beretta, Carmen De Caro, Pio Zoleo, Claudia Cagnetti, Miriam Olivieri, Fedele Dono, Cristina Politi, Antonio Gambardella, Pietro Mattioli, Emilio Russo, Marta Maschio, Alfredo D’Aniello, Francesco Deleo, Gianfranco Di Gennaro, Flavio Villani, Lorenzo Tinti, Chiara Bedetti, Ugo Leggio, Vincenzo Andreone, Giada Pauletto, Giovanni Boero, Francesca Felicia Operto, Roberto Cantello, Angelo Labate, Paolo Bonanni, Nicola Biagio Mercuri, Dario Arnaldi, Elisa Osanni, Claudio Liguori, Rosaria Renna, Matilde Lazzari, Giancarlo Di Gennaro, Luciano Antonio Nassar Pellegrino, Chiara Pastori, Filippo Dainese, Nicoletta Foschi, Edoardo Ferlazzo, Lara Buttarelli
article en
1 citations

Abstract

Treatment discontinuation in epilepsy emerges as a dynamic process shaped by both tolerability and clinical response. Early persistence was higher for LCM, whereas long-term retention was improved for BRV and PER. These results support a personalized approach to ASM selection that integrates early tolerability with sustained effectiveness.

Neurology and TherapyVol. 15(1)
University of Messina (IT), University of Rome Tor Vergata (IT), Marche Polytechnic University (IT), Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT), University of Udine (IT), University of Sannio (IT), University of Campania "Luigi Vanvitelli" (IT), Istituto Neurologico Mediterraneo (IT), Magna Graecia University (IT), University of Chieti-Pescara (IT), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Azienda Ospedaliera San Gerardo (IT), Azienda Ospedaliero Universitaria Maggiore della Carita (IT), Ospedale Santa Maria della Misericordia di Udine (IT), Azienda Socio Sanitaria Territoriale Lariana (IT), National Cancer Institute (MY), Ospedale Policlinico San Martino (IT), Ospedale SS. Annunziata (IT), Ospedale Maggiore di Lodi (IT), IRCCS Eugenio Medea (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), National Research Council (IT), Fondazione IRCCS Istituto Neurologico Carlo Besta (IT), University of Bari Aldo Moro (IT), University of Naples Federico II (IT), University of Genoa (IT)
Università degli Studi di Genova, Università degli Studi G. d'Annunzio Chieti - Pescara, Università degli Studi di Salerno, Università degli Studi di Roma Tor Vergata, Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze
Openalex Percentile: Top 13%
Epilepsy research and treatment
1.47
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.